Generic Glyburide

Buy Generic Glyburide () without prescription in Canada

In our Canadian pharmacy, you can buy Glyburide without a prescription, with delivery across Canada within 5-14 days. Discreet and anonymous packaging.

Glyburide (known as glyburide in Canada and glibenclamide in some other countries) is a sulfonylurea oral hypoglycaemic agent used to treat type 2 diabetes mellitus. It works by stimulating the pancreatic beta cells to release more insulin, and it also increases the sensitivity of peripheral tissues to insulin. This combined action helps lower blood glucose levels, especially after meals, and is used when diet, exercise, and weight reduction alone have not been sufficient to achieve glycaemic control.

Usual adult dose: The initial dose is 2.5 mg taken orally once daily with breakfast or the first main meal. If glucose control is inadequate, the dose may be increased by 2.5 mg at weekly intervals, up to a maximum of 20 mg per day, given in divided doses (typically twice daily) if the total daily dose exceeds 10 mg. The 5 mg tablet is often used when doses need to be escalated, or when starting at a higher dose in certain patients. The medication must be taken with food to prevent hypoglycaemia. Elderly patients and those with mild hepatic or renal impairment should start at the lowest possible dose of 2.5 mg and be titrated cautiously.

Dosage form: Oral tablets: 2.5 mg and 5 mg (as glyburide). A 1.25 mg tablet is also available in some markets.

Onset of action: The blood-glucose-lowering effect begins within 60 to 90 minutes after an oral dose, peaks at about 2 to 4 hours, and lasts for up to 12 to 24 hours, supporting once- or twice-daily dosing.

Duration of action: The elimination half-life of glyburide is approximately 10 hours, but its pharmacodynamic effect persists for 12 to 24 hours. Steady-state glucose control is typically achieved after 2 weeks of consistent daily dosing.

Alcohol recommendation: Alcohol consumption should be strictly limited or avoided during treatment with Glyburide. Alcohol can unpredictably lower blood sugar, leading to hypoglycaemia, and may also cause a disulfiram-like reaction (flushing, nausea, vomiting, and headache) in some patients. Additionally, chronic heavy alcohol intake can impair liver function and interfere with glucose regulation. Patients should discuss safe limits with their physician; in general, alcohol should be consumed only in moderation, with food, and never on an empty stomach.

Most common side effects: Hypoglycaemia (low blood sugar) is the most common and most serious side effect, with symptoms including sweating, shakiness, dizziness, confusion, and palpitations. Weight gain, gastrointestinal disturbances (nausea, epigastric fullness, heartburn), and headache are also common. Rare but serious effects include cholestatic jaundice, leukopenia, thrombocytopenia, and hyponatraemia. Glyburide is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, and severe hepatic or renal impairment.

Would you like to try Glyburide without a prescription?

General Information about Glyburide

• INN (International Nonproprietary Name): Glyburide (glibenclamide)
• Brand names available in Canada: Diabeta® (Sanofi-Aventis Canada Inc.) is the primary brand-name product. Generic versions are widely available and include APO-Glyburide (Apotex Inc.), TEVA-Glyburide (Teva Canada Limited), Sandoz Glyburide (Sandoz Canada Inc.), PMS-Glyburide (Pharmascience Inc.), and others.
• ATC code: A10BB01 (glyburide; sulfonylureas)
• Dosage forms and strengths: Oral tablets: 2.5 mg and 5 mg. A 1.25 mg tablet is also available in Canada but the 2.5 mg and 5 mg are the most commonly prescribed strengths.
• Manufacturers in Canada: Sanofi-Aventis Canada Inc. (Diabeta), Apotex Inc., Teva Canada Limited, Sandoz Canada Inc., Pharmascience Inc., and other generic manufacturers.
• Registration status in Canada: Approved by Health Canada. Marketed. DINs: 00274214 (Diabeta 2.5 mg), 00274222 (Diabeta 5 mg), and numerous generic DINs. Glyburide has been available in Canada for decades.
• OTC / Rx classification: Prescription only (Rx). Schedule I drug under the Controlled Drugs and Substances Act. A valid prescription from a licensed Canadian healthcare professional is required.

Mechanism of Action and Pharmacology

Glyburide is a second-generation sulfonylurea that exerts its hypoglycaemic effect primarily by binding to the sulfonylurea receptor (SUR1) on pancreatic beta cells, which closes ATP-sensitive potassium channels. This leads to cell membrane depolarization, opening of voltage-gated calcium channels, influx of calcium, and exocytosis of insulin-containing granules. It therefore increases both basal and meal-stimulated insulin secretion. Glyburide also has mild peripheral effects, increasing insulin sensitivity in muscle and adipose tissue. Because its action depends on functioning beta cells, it is ineffective in patients with type 1 diabetes or those who have undergone pancreatectomy. The drug is metabolized in the liver to weakly active metabolites, which are excreted in urine (about 50%) and faeces. The elimination half-life is about 10 hours, but the pharmacodynamic effect can last up to 24 hours, allowing once-daily dosing in many patients. However, because glyburide has a relatively long duration of action compared with some other sulfonylureas, it carries a higher risk of prolonged and severe hypoglycaemia, especially in the elderly and those with renal impairment.

Indications

• Management of type 2 diabetes mellitus as an adjunct to diet and exercise when lifestyle modifications alone fail to achieve adequate glycaemic control.
• May be used in combination with other oral antidiabetic agents (e.g., metformin, pioglitazone) or insulin when monotherapy is insufficient.
• Not indicated for the treatment of type 1 diabetes, diabetic ketoacidosis, or diabetic coma.

Important Warnings and Precautions

At‑risk groups

• Pregnancy: Glyburide is generally not recommended during pregnancy. Insulin is the preferred agent for glycaemic control in pregnant women with diabetes. Glyburide crosses the placenta and has been associated with neonatal hypoglycaemia. It should be used during pregnancy only if the potential benefit clearly justifies the potential risk, and only under specialist care. Women of childbearing potential should inform their physician if they become pregnant while taking glyburide.
• Breastfeeding: Glyburide is excreted in human breast milk in small amounts. It is generally considered compatible with breastfeeding, but the infant should be monitored for signs of hypoglycaemia (irritability, drowsiness, poor feeding). A decision should be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of the medication to the mother.
• Paediatrics: Safety and efficacy in children have not been established. Glyburide is not typically used in paediatric patients.
• Elderly: Elderly patients are particularly susceptible to hypoglycaemic reactions. The lowest effective dose should be used, starting with 2.5 mg or less. Renal function should be assessed before and during therapy, as reduced renal clearance increases the risk of accumulation and prolonged hypoglycaemia. Glyburide is included in the Beers Criteria as a potentially inappropriate medication for older adults due to its high risk of severe, prolonged hypoglycaemia. Shorter-acting sulfonylureas (e.g., gliclazide) are often preferred in this population.
• Renal impairment: Glyburide is contraindicated in severe renal impairment (eGFR < 30 mL/min/1.73 m²). In moderate renal impairment, the dose must be reduced, and glucose monitored closely. Accumulation of active metabolites can cause severe and prolonged hypoglycaemia.
• Hepatic impairment: Use with caution in patients with hepatic disease. Glyburide is metabolized in the liver, and its clearance may be reduced. Liver function tests should be monitored, and the dose adjusted as needed. It is contraindicated in severe hepatic impairment.
• Cardiovascular disease: Like all sulfonylureas, glyburide should be used with caution in patients with cardiovascular disease. There is a potential for increased cardiovascular mortality, as suggested by the University Group Diabetes Program (UGDP) study, although this remains controversial. Clinicians should weigh the benefits against the potential risks.
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Glyburide may cause haemolytic anaemia in patients with G6PD deficiency. Alternative therapy should be considered.
• Hypoglycaemia: All sulfonylureas are capable of producing severe hypoglycaemia, which can lead to coma or death. Patients must be educated on the recognition of hypoglycaemic symptoms and the importance of regular meals, never skipping a meal after taking glyburide. The dose should be initiated at the lowest possible level and titrated slowly. Alcohol, strenuous exercise, and drug interactions can increase the risk.
• Allergy: Do not take Glyburide if you have a known hypersensitivity to glyburide, other sulfonylureas, sulfonamides, or any excipient in the tablet.

Driving and alcohol

Glyburide can cause hypoglycaemia, which may impair the ability to concentrate and react. Patients should be advised to take precautions to avoid hypoglycaemia while driving, such as checking blood glucose before driving, carrying a fast-acting carbohydrate source (e.g., glucose tablets, fruit juice), and not delaying or missing meals. Alcohol should be strictly limited or avoided because it can unpredictably and profoundly lower blood sugar, mask the warning signs of hypoglycaemia, and cause a disulfiram-like reaction. Alcohol should be consumed only with food and in moderation, if at all.

Dosage Instructions

• Initial dose: 2.5 mg once daily with breakfast or the first main meal. If glycemic control is not achieved, the dose may be increased by 2.5 mg at weekly intervals, up to a maximum of 20 mg per day. Doses above 10 mg daily are usually divided into two doses (e.g., morning and evening meal) to minimize the risk of hypoglycaemia and improve postprandial control.
• Elderly, debilitated, or malnourished patients: Start with 2.5 mg or even 1.25 mg once daily and titrate very cautiously to avoid hypoglycaemia. The maintenance dose is often lower than in younger adults.
• Administration: The tablet should be swallowed whole with a glass of water, taken with a meal to reduce gastrointestinal upset and to align the peak insulin effect with post-meal glucose rise. Adherence to the prescribed meal plan and timing of doses is critical to prevent hypoglycaemia.
• Missed dose: If a dose is missed, it should be taken with the next meal, provided the patient is eating. Do not double the dose if it is close to the time of the next scheduled dose. If a meal is missed, the dose should also be skipped to avoid hypoglycaemia.
• Discontinuation: When transitioning to other therapies or if the drug is no longer needed, the dose should be gradually reduced under medical supervision to avoid rebound hyperglycaemia.

Side Effects and Contraindications

• Very common side effects (≥ 10%): Hypoglycaemia (1-5% with severe events less common), weight gain (1-3 kg over the first year), and gastrointestinal disturbances (nausea, heartburn, epigastric fullness).
• Common side effects (1-10%): Headache, dizziness, and skin rash (including urticaria).
• Serious adverse reactions: Severe and prolonged hypoglycaemia (may require hospitalisation, particularly in the elderly and those with renal impairment); cholestatic jaundice and hepatitis; blood dyscrasias (leukopenia, thrombocytopenia, haemolytic anaemia, aplastic anaemia); hyponatraemia (SIADH); and allergic interstitial nephritis. Disulfiram-like reactions with alcohol have been reported.
• Contraindications: Type 1 diabetes mellitus; diabetic ketoacidosis, with or without coma; severe renal impairment (eGFR < 30 mL/min); severe hepatic impairment; known hypersensitivity to glyburide, sulfonylureas, or sulfonamides; pregnancy (relative, use only if benefit outweighs risk).

Drug Interactions

• Alcohol — major interaction: Alcohol can produce a disulfiram-like reaction and severe hypoglycaemia. Avoid or strictly limit alcohol intake.
• Drugs that potentiate the hypoglycaemic effect — increased risk of low blood sugar: Non-steroidal anti-inflammatory drugs (NSAIDs), salicylates, sulfonamides, chloramphenicol, probenecid, coumarin anticoagulants, monoamine oxidase inhibitors (MAOIs), beta-adrenergic blocking agents, and cimetidine can displace glyburide from protein binding or inhibit its metabolism, leading to enhanced hypoglycaemic activity. Doses may need to be reduced.
• Drugs that produce hyperglycaemia — loss of glucose control: Thiazide diuretics, corticosteroids, phenytoin, niacin, estrogens (including oral contraceptives), phenothiazines, thyroid hormones, and sympathomimetics (e.g., salbutamol, ritodrine) can raise blood glucose, potentially requiring an increase in glyburide dose.
• Beta-blockers — masking of hypoglycaemia: Beta-adrenergic blocking agents, especially non-selective ones (e.g., propranolol), can mask the adrenergic warning signs of hypoglycaemia (tachycardia, palpitations, tremor) and prolong recovery. Caution is advised.
• Warfarin — possible interaction: Glyburide may potentiate or antagonize the anticoagulant effect of warfarin; INR monitoring is recommended when initiating or discontinuing glyburide.
• Cyclosporine — increased cyclosporine levels: Glyburide may increase cyclosporine plasma concentrations and potentially increase nephrotoxicity; cyclosporine levels should be monitored.
• Colesevelam — reduced absorption: Colesevelam, a bile acid sequestrant, reduces the absorption of glyburide. Glyburide should be taken at least 4 hours before colesevelam.

Practical Advice

• Administration: Take glyburide with breakfast or your first main meal. If you take more than 10 mg daily, divide the total dose into two smaller doses, one with breakfast and one with your evening meal. Swallow the tablet whole with water; the scored tablet can be split if a lower dose is needed. Never take the medication on an empty stomach. Follow your prescribed diet and exercise programme strictly.
• Monitoring: Self-monitor blood glucose as directed by your physician. Glycosylated haemoglobin (HbA1c) should be measured every 3-6 months. Renal function and liver enzymes should be assessed before starting therapy and periodically thereafter. Patients should be educated on the signs and symptoms of hypoglycaemia (sweating, dizziness, confusion, hunger, tremor) and instructed to carry a fast-acting carbohydrate at all times. Weight should be monitored regularly.
• Storage: Store at room temperature (15-30 °C) in a dry place, protected from moisture and light. Keep the container tightly closed and out of the reach and sight of children.
• Lifestyle: Glyburide is not a substitute for a healthy diet. Weight loss, regular physical activity, and good nutrition are fundamental to managing diabetes. Wear a medical alert bracelet or carry a card identifying that you have diabetes and are taking a sulfonylurea. Avoid alcohol or drink only in moderation, with food, and never when your blood sugar is already low. If you experience frequent hypoglycaemic episodes, contact your doctor; your dose may need to be reduced.
• Missed dose: If you miss a dose, take it with your next meal. If you are not eating, skip the dose. Do not take a double dose to make up for a missed one.
• When to seek medical review: Contact your doctor if you experience unexplained hypoglycaemia, jaundice (yellowing of the skin or eyes), dark urine, persistent nausea or vomiting, easy bruising or bleeding, signs of infection, or an allergic reaction. Seek emergency medical attention for severe hypoglycaemia (loss of consciousness, seizures) or anaphylaxis.
• Disposal: Return unused or expired medication to a pharmacy for safe disposal. Do not flush down the toilet or discard in household waste.

Alternative Medications

• Other sulfonylureas: Gliclazide (Diamicron®), glimepiride (Amaryl®), and gliclazide MR (Diamicron MR®) are second- and third-generation sulfonylureas with shorter half-lives and a lower risk of severe, prolonged hypoglycaemia, especially in the elderly and those with renal impairment. They are often preferred over glyburide in these populations.
• Metformin (Glucophage®): The first-line oral agent for type 2 diabetes, which works primarily by reducing hepatic glucose production and improving insulin sensitivity. It does not cause hypoglycaemia when used as monotherapy and is weight-neutral or promotes modest weight loss. Metformin is often combined with glyburide when a single agent is insufficient.
• DPP-4 inhibitors (gliptins): Sitagliptin (Januvia®), saxagliptin (Onglyza®), and linagliptin (Trajenta®) enhance the body’s own incretin system to increase insulin secretion in a glucose-dependent manner, with a low risk of hypoglycaemia and weight neutrality.
• SGLT2 inhibitors: Empagliflozin (Jardiance®) and dapagliflozin (Forxiga®) lower blood glucose by blocking glucose reabsorption in the kidneys, with additional benefits for heart failure and weight loss. They do not cause hypoglycaemia on their own.
• GLP-1 receptor agonists: Liraglutide (Victoza®) and semaglutide (Ozempic®) are injectable agents that increase insulin secretion, suppress glucagon, and promote weight loss.
• Insulin therapy: Ultimately, many patients with type 2 diabetes will require insulin, either alone or in combination with oral agents, as their disease progresses.

Clinical Efficacy

Glyburide has been used for type 2 diabetes since the 1970s and is effective at lowering HbA1c by 1-2% when used as monotherapy or in combination with other agents. In the United Kingdom Prospective Diabetes Study (UKPDS), sulfonylureas, including glyburide, significantly reduced microvascular complications when intensive glucose control was achieved. However, glyburide is associated with a higher risk of hypoglycaemia than many newer agents, particularly in the elderly and those with renal impairment. Canadian clinical practice guidelines now generally recommend other sulfonylureas (e.g., gliclazide) or metformin as first-line oral therapies, with glyburide reserved for specific situations where cost or availability are factors, or where the patient has been stable on it for a long time. The 2.5 mg and 5 mg strengths allow flexible dosing to meet individual patient needs.

Important:

Glyburide is a prescription medication that should be used only under the supervision of a qualified healthcare professional. It can cause severe and prolonged hypoglycaemia, which can be life-threatening and may require emergency treatment. You must follow your prescribed diet and never skip a meal after taking glyburide. Alcohol consumption must be strictly limited or avoided, as it can unpredictably worsen hypoglycaemia. Elderly patients, those with kidney disease, and those taking multiple medications are at the highest risk. Always carry a fast-acting sugar source with you. If you experience signs of hypoglycaemia (sweating, shakiness, confusion), check your blood sugar and treat immediately. This medication is not for type 1 diabetes. Do not use glyburide if you are pregnant or planning pregnancy without consulting your doctor. This information is not a substitute for professional medical advice, diagnosis, or treatment.

Get Generic Glyburide - Shipping across Canada